Psychedelics and Terminal Illness: What the Research Shows

Anxiety, depression and distress when facing a life-threatening illness. Research summaries and safety screening; Gabriel doesn't give psychedelic dosing.

Overview

A serious diagnosis often brings anxiety, depression and questions about meaning alongside physical symptoms. Some of the most cited psychedelic research has studied this distress in people with cancer.

Trials included medical screening, preparation, a supervised session and follow-up support.

Substances Being Studied

Psilocybin

Strong

Psilocybin is a naturally occurring psychedelic compound found in more than 200 species of mushrooms. In the body it converts to psilocin, which activates serotonin 5-HT2A receptors in the brain, changing perception, mood and thinking for several hours. In clinical trials, psilocybin given with psychological support has reduced depression symptoms within days, with effects lasting weeks to months for some participants. Compass Pathways has run two Phase 3 trials of COMP360, a synthetic psilocybin, for treatment-resistant depression: in COMP005 (results June 2025) it beat placebo by 3.6 points on the MADRS depression scale at week 6, and in COMP006 (results February 2026) it beat a very low comparison dose by 3.8 points. As of October 2026, psilocybin is not FDA-approved; Compass says it is completing its application to FDA. Researchers at Johns Hopkins, NYU Langone, Imperial College London and other centers have also studied psilocybin for anxiety and depression in people with cancer, alcohol and tobacco use disorders, and obsessive-compulsive disorder. Trials pair it with preparation and follow-up sessions with trained therapists, and screen people carefully before treatment.

Learn more →

LSD

Moderate

LSD (lysergic acid diethylamide) is a potent semi-synthetic psychedelic first made by Albert Hofmann at Sandoz Laboratories in 1938. It activates serotonin 5-HT2A receptors and changes perception, mood and thinking for 8 to 12 hours. In the 1950s and 60s it was studied for alcoholism and anxiety before research stopped under prohibition. Modern trials have returned: Definium Therapeutics (formerly MindMed) reported positive Phase 3 results for its LSD drug candidate, DT120, in major depression (Emerge, June 2026) and generalized anxiety disorder (Voyage, August 2026), where it reduced symptoms more than placebo. As of October 2026, LSD is not FDA-approved; the company has said it plans to apply in 2027. A 2025 phase 2a trial of repeated low doses of LSD for adult ADHD did not beat placebo on its primary outcome. Earlier work at the University of Basel studied LSD-assisted therapy for anxiety in people with life-threatening illness, and neuroimaging studies at Imperial College London showed how LSD changes communication between brain networks.

Learn more →

What the Research Shows

Two randomized trials published in 2016, at Johns Hopkins and NYU, found that psilocybin with psychological support reduced anxiety and depression in people with life-threatening cancer, and follow-up studies reported lasting benefits for many participants. Earlier work at the University of Basel studied LSD-assisted therapy for anxiety in serious illness. As of October 2026, no psychedelic is FDA-approved for this use.

Safety Considerations

  • •Medical clearance is needed, given the person's overall health and medicines.
  • •Needs sensitive, licensed therapeutic support.
  • •Many people involve family in preparation and follow-up.

Safety screening

Psychedelics are not safe for everyone. Talk with a licensed clinician first, especially if any of these apply to you:

  • Antidepressants such as SSRIs and SNRIs, and other medicines that raise serotonin (tramadol, for example): they can blunt the effect of psychedelics, and with some substances, such as MDMA and ayahuasca, raise the risk of serotonin syndrome.
  • Lithium: seizures have been reported when lithium is combined with classic psychedelics such as psilocybin and LSD.
  • MAOIs, including the MAOIs in ayahuasca: dangerous interactions with many medicines, other substances and some foods.
  • Heart disease, high blood pressure, or a heart rhythm problem such as long QT syndrome.
  • A personal or family history of psychosis, schizophrenia or bipolar disorder.
  • Pregnancy or breastfeeding.

Never stop or change a prescribed medicine without your prescriber.

Gabriel doesn't give psychedelic dosing and doesn't help anyone obtain psychedelics. This page explains research and risks; it is not medical advice.

If you're in crisis, call or text 988 (Suicide and Crisis Lifeline). For a medical emergency, call 911.

Questions? Ask Gabriel

Gabriel can help you find and book licensed clinicians who offer ketamine or esketamine treatment. Gabriel doesn't prescribe ketamine.

Ask Gabriel

Explore Other Conditions

See what the research shows for other mental health, substance use and pain conditions.